According to research data released at a medical conference on Saturday, Amgen's drug Imdelltra in combination with AstraZeneca immunotherapy Imfinzi can reduce the risk of death in patients with widespread small cell lung cancer by 58% compared to using AstraZeneca alone. For this extremely aggressive and difficult to treat disease, Imfinzi is currently the standard treatment plan after chemotherapy if the patient's condition does not worsen after initial chemotherapy. The study found that patients treated with both medications had a median survival of 21.1 months, while those treated with Imfinzi alone had a median survival of 12.7 months. “The sooner you use Imdelltra, the greater the clinical benefits,” said Burton, chief medical officer at Amgen, California. He called the results “unprecedented in advancing the treatment of widespread small cell lung cancer.”

According to research data released at a medical conference on Saturday, Amgen's drug Imdelltra in combination with AstraZeneca immunotherapy Imfinzi can reduce the risk of death in patients with widespread small cell lung cancer by 58% compared to using AstraZeneca alone. For this extremely aggressive and difficult to treat disease, Imfinzi is currently the standard treatment plan after chemotherapy if the patient's condition does not worsen after initial chemotherapy. The study found that patients treated with both medications had a median survival of 21.1 months, while those treated with Imfinzi alone had a median survival of 12.7 months. “The sooner you use Imdelltra, the greater the clinical benefits,” said Burton, chief medical officer at Amgen, California. He called the results “unprecedented in advancing the treatment of widespread small cell lung cancer.”